These Ku–DNA binding inhibitors (Ku-DBi's) display nanomolar activity in vitro, inhibit cellular DNA-PK and NHEJ-catalyzed DSB repair, and sensitize non-small cell lung cancer (NSCLC) cells to DSB-inducing agents. This evidence concerns the gene PRKDC and non-small cell lung carcinoma.